Search company, investor...
Visiopharm company logo


Founded Year



Unattributed VC | Alive

Total Raised


About Visiopharm

Visiopharm is a provider of quantitative image analysis software and end-to-end Digital Pathology solutions for Hospitals, biopharmaceutical companies, and research institutions around the world. Products include ONCOTOPIX Diagnostics, a robust solution for cancer diagnostics with CE-IVD algorithms for the breast panel, integrated LIS driven workflow, and VirtualDoubleStaining.

Headquarters Location

Agern Allé 24

Hoersholm, 2970,


+45 88 20 20 88

Missing: Visiopharm's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Visiopharm's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Visiopharm

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Visiopharm is included in 7 Expert Collections, including Digital Health.


Digital Health

21,956 items

Startups recreating how healthcare is delivered


Artificial Intelligence

9,442 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.


Medical Devices

8,553 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.


Health IT

10,540 items

This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.

Visiopharm Patents

Visiopharm has filed 1 patent.

The 3 most popular patent topics include:

  • Archaeological artefact types
  • Artificial intelligence
  • Artificial neural networks
patents chart

Application Date

Grant Date


Related Topics




Machine learning, Artificial neural networks, Natural language processing, Artificial intelligence, Computational linguistics


Application Date


Grant Date



Related Topics

Machine learning, Artificial neural networks, Natural language processing, Artificial intelligence, Computational linguistics



Latest Visiopharm News

Deep Bio and Visiopharm Announce a Collaborative Integration of a Clinical-Grade AI Prostate Cancer Solution with a Leading Digital Pathology Platform

Nov 21, 2022

Share Deep Bio , a leading AI biotech dedicated to cancer diagnosis, and Visiopharm, a world leader in AI-powered image analysis and tissue mining for research and diagnostics, announced a strategic partnership to provide pathologists access to the latest AI-powered prostate cancer solution. AI-powered cancer diagnostics has been proving its utility not only in research, but increasingly in supporting and improving pathologists’ decisions, workflow efficiency, and diagnostic precision. Deep Bio’s deep learning-based CE-IVDD prostate cancer diagnosis support software, DeepDx Prostate, empowers pathologists by identifying cancerous areas and grading their severity providing a Gleason scoring. With this collaboration, DeepDx strengthens Visiopharm’s diagnostic offering to its European diagnostic customers. This application expands pathologists’ accessibility to the latest cutting-edge H&E-based AI solutions for prostate cancer, which today is a large diagnostic indication that is both time and labor-intensive in diagnostic pathology labs. With its extensive AI-based image analysis solutions for multiple cancer types, Visiopharm’s platform is contributing to the global adoption of digital pathology and AI. The first phase of integration of DeepDx into Visiopharm’s digital pathology platform has been completed. In the next phases, Visiopharm will together with Deep Bio scale up the solution as interest grows. The two companies plan to add additional AI cancer pathology solutions over time for prostate and breast, among others. Related Posts “Digital transformation in healthcare is not a new concept anymore. Pathology, which has been slow to undergo digital transformation, is fast becoming digitalized due to a diverse range of AI solutions now available for implementation and validation”, said Sun Woo Kim , the CEO of Deep Bio. “Our dedication to AI for digital pathology has taken a major step forward with this collaboration and we are pleased to offer our latest technology to more labs and hospitals across the world through this opportunity. We will continue to support medical professionals to optimize their decisions which ultimately lead to the best patient care,” he added. The second phase of integration will aim for tighter interoperability among the platform and AI solutions, helping both companies to better promote and distribute to healthcare institutions around the world. Michael Grunkin, CEO of Visiopharm said, “We are seeing a lot of demand for this particular application among both our clinical research- and diagnostic customers and partners. In diagnostic workflows, this APP has the potential to support pathologists in automating time-consuming and repetitive work, while improving turn-around-time and standardization. This partnership with Deep Bio is a good example of how our scanner, LIMS, and PACS agnostic platform allow our users to benefit both from our own apps and best-in-class apps from our growing partner network, to gain access to a full diagnostic menu.”

Visiopharm Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Visiopharm Rank

Visiopharm Frequently Asked Questions (FAQ)

  • When was Visiopharm founded?

    Visiopharm was founded in 2001.

  • Where is Visiopharm's headquarters?

    Visiopharm's headquarters is located at Agern Allé 24, Hoersholm.

  • What is Visiopharm's latest funding round?

    Visiopharm's latest funding round is Unattributed VC.

  • How much did Visiopharm raise?

    Visiopharm raised a total of $2.62M.

  • Who are the investors of Visiopharm?

    Investors of Visiopharm include Northcap Partners, BankInvest Group, ATP Capital, Vækstfonden, C.L. Davids Fond og Samling and 3 more.

  • Who are Visiopharm's competitors?

    Competitors of Visiopharm include Metabolon, Ibex Medical Analytics, AIRA Matrix, BioDiscovery, Cancer Center and 15 more.

Compare Visiopharm to Competitors

Heptares Therapeutics

Heptares Therapeutics focuses on the discovery and development of novel drugs acting at G-protein coupled receptors (GPCRs). Heptares StaR (Stabilized Receptor) technology enables thermo-stabilization of GPCRs, a breakthrough allowing X-ray crystallography of conformationally-constrained receptors, thereby facilitating structure-based drug design at GPCRs that have been resistant to traditional methods of drug screening.


Novadrug is a drug discovery company geared toward the identification of effective antimicrobial, antiviral, immunosuppressive and anticancer drugs.

Metabolon Logo

Metabolon is a health technology company focused on metabolomics. It offers a tool for precision medicine and life sciences research. The company's platforms and informatics deliver biomarker discoveries, diagnostic tests, and partnerships in genomics-based, health initiatives. Metabolon was founded in 2000 and is based in Morrisville, North Carolina.


Xention is a Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs. The Company has potential breakthrough drugs for atrial fibrillation, an area in which it has developed considerable expertise.


Celecure AS does drug discovery and development of anticancer drugs. Celecure is the R&D unit of Celecure Group, an estonian biotech company.


SULFIDRIS, a spin-off of Milan University, is a drug-discovery company. nSULFIDRIS is focused in R&D of drugs (SULFIDRACs) for the treatment of cancer disorders. nSULFIDRACs are multi-modal safe and effective drugs, capable to act on redox-imbalance-related pathogenetic mechanisms.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.